Drug Trial Radar · NCT07486089
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Feb 14, 2027
Study completion Mar 17, 2028
Sponsor
- Lead sponsor
- Beijing BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Conditions
- Breast Cancer (Locally Advanced or Metastatic)
- HER2-positive Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
Interventions
Dual-target CAR-NK cells (EB-DT-CAR-NK)Biological
Route: IV infusion. Schedule: single infusion on Day 0; optional second infusion on Day 7 in the absence of dose-limiting toxicity (DLT) and with adequate clinical status.
Lymphodepleting chemotherapyDrug
fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4), prior to CAR-NK infusion.
Supportive careOther
Premedication per institutional standard (e.g., acetaminophen and antihistamine). Tumor lysis and infection prophylaxis per institutional guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs)Time frame: 28 Days
- Safety profileTime frame: 12 months
- Recommended Phase 2 DoseTime frame: 56 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.